Foghorn Therapeutics: Foghorn Therapeutics to Host Virtual Investor Event to Review Pipeline Updates in Conjunction with 2025 AACR Annual Meeting

Company to share new preclinical combination data for FHD-909 (LY4050784), a potential first-in-class selective SMARCA2 inhibitor, with non-small cell lung cancer (NSCLC) as the primary target populationAdditional updates include new preclinical data for Selective CBP degrader program in combination with chemotherapy and targeted agents and for Selective EP300 degrader program in hematological malignanciesVirtual investor event to be held on Tuesday April 29, 2025, at 8 a.m. ET CAMBRIDGE, Mass., April 15, 2025 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced that it will host a virtual investor event on April 29th at 8:00 a.m. ET to review key pipeline updates in conjunction with the 2025 American Association for Cancer Research (AACR) Annual Meeting being held April 25-30, 2025.Foghorn management will review updates for FHD-909, a potential first-in-class selective SMARCA2 inhibitor, including new preclinical combination data being presented at the 2025 AACR Annual Meeting. In addition, the company will share new preclinical data from their Selective CBP degrader and Selective EP300 degrader programs and provide an overview of their Selective ARID1B ...Full story available on Benzinga.com